Gujarat Kidney Super Speciality Ltd vs Maestros Electronics Telecommun Systems Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Nov 01, 2026

Key Highlights

The Latest Trading Price of Gujarat Kidney & Super Speciality Ltd is ₹ 163.5 as of 30 Oct 15:30 . The P/E Ratio of Gujarat Kidney & Super Speciality Ltd changed from 51.4 on March 2026 to 0 on March 2023 . This represents a CAGR of -100.00% over 2 yearsThe P/E Ratio of Maestros Electronics & Telecommun. Systems Ltd changed from 12.2 on March 2024 to 0 on March 2023 . This represents a CAGR of -100.00% over 4 years The Market Cap of Gujarat Kidney & Super Speciality Ltd changed from ₹ 798.29 crore on March 2026 to ₹ 0 crore on March 2023 . This represents a CAGR of -100.00% over 2 yearsThe Market Cap of Maestros Electronics & Telecommun. Systems Ltd changed from ₹ 60.31 crore on March 2024 to ₹ 0 crore on March 2023 . This represents a CAGR of -100.00% over 4 years The revenue of Gujarat Kidney & Super Speciality Ltd for the Jun '26 is ₹ 34.98 crore as compare to the Mar '26 revenue of ₹ 31.29 crore. This represent the growth of 11.79% The revenue of Maestros Electronics & Telecommun. Systems Ltd for the Jun '26 is ₹ 10.61 crore as compare to the Mar '26 revenue of ₹ 12.81 crore. This represent the decline of -17.17% The ebitda of Gujarat Kidney & Super Speciality Ltd for the Jun '26 is ₹ 9.07 crore as compare to the Mar '26 ebitda of ₹ 7.01 crore. This represent the growth of 29.39% The ebitda of Maestros Electronics & Telecommun. Systems Ltd for the Jun '26 is ₹ 2.4 crore as compare to the Mar '26 ebitda of ₹ 3.13 crore. This represent the decline of -23.32% The net profit of Gujarat Kidney & Super Speciality Ltd changed from ₹ 2.96 crore to ₹ 5.32 crore over 9 quarters. This represents a CAGR of 29.77% The net profit of Maestros Electronics & Telecommun. Systems Ltd changed from ₹ 1.25 crore to ₹ 1.67 crore over 9 quarters. This represents a CAGR of 13.74% The Dividend Payout of Gujarat Kidney & Super Speciality Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Maestros Electronics & Telecommun. Systems Ltd changed from 22.04 % on March 2022 to 0 % on March 2026 . This represents a CAGR of -100.00% over 5 years .

About Gujarat Kidney & Super Speciality Ltd

Gujarat Kidney And Super Speciality Limited was incorporated under the name and style of Vihaan Medicare Private Limited', a private limited company, dated December 20, 2019 issued by the Registrar of Companies, Central Registration Centre.
Subsequently, the Company name was changed to Gujarat Kidney and Super Speciality Private Limited' and a fresh certificate of incorporation dated September 13, 2023 was issued by the Registrar of Companies, Gujarat at Ahmedabad.
Further, Company' status was changed to a public limited company and the name of Company was changed to Gujarat Kidney and Super Speciality Limited' dated November 24, 2023 by the ROCs, Ahmedabad. The Company operate a chain of mid-sized multispecialty healthcare institution and is engaged in providing comprehensive medical services, including inpatient and outpatient care, surgical procedures, diagnostic services, and emergency care.

About Maestros Electronics & Telecommun. Systems Ltd

Maestros Electronics & Telecommunications Systems Limited was incorporated on February 19, 2010.
At present, Company is engaged in activities pertaining to design, development, and manufacturing of creating products and services for financial inclusion, cardiology, gynecology, critical care patient and diseases management in medicine with rich experience in latest technologies and communication. It provide an advanced portfolio of products and services, including patient monitors, electrocardiographs, defibrillators, pulse oximeters, fetal monitors, stress test systems and much more. With state-of-the-art R&D and manufacturing facilities located in Mumbai, India, Company excel in creating cutting-edge solutions tailored to the needs of clients.
It mainly operates into two segments viz, Electronics & Instrumentation (E&T) and Telemedicine.

FAQs for the comparison of Gujarat Kidney & Super Speciality Ltd and Maestros Electronics & Telecommun. Systems Ltd

Which company has a larger market capitalization, Gujarat Kidney & Super Speciality Ltd or Maestros Electronics & Telecommun. Systems Ltd?

Market cap of Gujarat Kidney & Super Speciality Ltd is 1,289 Cr while Market cap of Maestros Electronics & Telecommun. Systems Ltd is 84 Cr

What are the key factors driving the stock performance of Gujarat Kidney & Super Speciality Ltd and Maestros Electronics & Telecommun. Systems Ltd?

The stock performance of Gujarat Kidney & Super Speciality Ltd and Maestros Electronics & Telecommun. Systems Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Gujarat Kidney & Super Speciality Ltd and Maestros Electronics & Telecommun. Systems Ltd?

As of November 1, 2026, the Gujarat Kidney & Super Speciality Ltd stock price is INR ₹163.5. On the other hand, Maestros Electronics & Telecommun. Systems Ltd stock price is INR ₹77.0.

How do dividend payouts of Gujarat Kidney & Super Speciality Ltd and Maestros Electronics & Telecommun. Systems Ltd compare?

To compare the dividend payouts of Gujarat Kidney & Super Speciality Ltd and Maestros Electronics & Telecommun. Systems Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.